The development of combretastatin A4 phosphate as a vascular targeting agent

International Journal of Radiation Oncology Biology Physics

Volumn 54, Issue 5, 2002, Pages 1491-1496

  Chaplin, David J ^a   Hill, Sally A ^b  

^a Oxigene Inc   (United States)

^b MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

Combretastatin A4 phosphate; Tumor cell survival; Tumor vasculature; Vascular targeting

Indexed keywords

ASSAYS; CELLS; FLUORESCENCE; HISTOLOGY; MICROSCOPIC EXAMINATION; TUMORS;

RETARDATION;

ONCOLOGY;

CISPLATIN; COLCHICINE; COMBRETASTATIN A4; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; IRINOTECAN; MELPHALAN; PACLITAXEL;

ANIMAL CELL; BIOASSAY; CANCER THERAPY; CELL DEATH; CELL GROWTH; CELL VIABILITY; CONFERENCE PAPER; CONTROLLED STUDY; DEPOLYMERIZATION; DRUG IDENTIFICATION; DRUG SCREENING; EXCISION; FLUORESCENCE MICROSCOPY; GROWTH RETARDATION; HISTOLOGY; IMPLANTATION; MACROMOLECULE; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PERFUSION; PRIORITY JOURNAL; TUMOR CELL; TUMOR VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BENZIMIDAZOLES; DOSE-RESPONSE RELATIONSHIP, DRUG; MICE; MICE, INBRED CBA; MICROSCOPY, FLUORESCENCE; NECROSIS; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; RADIATION-PROTECTIVE AGENTS; STILBENES; TIME FACTORS; TUBULIN; TUMOR CELLS, CULTURED;

EID: 0036891515     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(02)03924-X     Document Type: Conference Paper

References (37)

1. Denekamp J., Hill S.A., Hobson B. Vascular occlusion and tumour cell death. Eur J Cancer Clin Oncol. 19:1983;271-275.
2. Chaplin D.J., Horsman M.R. The influence of tumour temperature on ischemia-induced cell death Potential implications for the evaluation of vascular mediated therapies . Radiother Oncol. 30:1994;59-65.
3. Parkins C.S., Hill S.A., Lonergan S.J., et al. Ischaemia induced cell death in tumors Importance of temperature and pH . Int J Radiat Oncol Biol Phys. 29:1994;499-503.
4. Denekamp J. Endothelial cell attack as a novel approach to cancer therapy. Cancer Topics. 6:1986;6-8.
5. Denekamp J. Vascular attack as a therapeutic strategy for cancer. Cancer Metastasis Rev. 9:1990;267-282.
6. Walsh. The anatomy, physiology, pathology and treatment of cancer. London. 1844.
7. Woglum W.H. A critique of tumour resistance. J Cancer Res. 7:1923;283-311.
8. Coley Nauts H., Fowler G.A., Bogatko F.H. A review of the influence of bacterial infection and bacterial products (Coley's toxins) on malignant tumours in man. Acta Med Scand. 274:(Suppl.):1953;29-97.
9. Mottram J.C. Observations on the combined action of colloidal lead and radiation on tumours. Br Med J. 1:1928;928.
10. Boyland E., Boyland M.E. Studies in tissue metabolism. IX. The action of colchicine and B. typhosus extract. Biochem J. 31:1937;454-460.
11. Ludford R.J. Colchicine in the experimental chemotherapy of cancer. J Natl Cancer Inst. 6:1945;89-101.
12. Ludford R.J. Factors determining the action of colchicine on tumour growth. Br J Cancer. 2:1948;75-86.
13. Seed L., Slaughter D.P., Limarzi L.R. Effect of colchicine on human carcinoma. Surgery. 7:1940;696-709.
14. Algire G.H., Legallais F.Y., Anderson B.F., et al. Vascular reactions of normal and malignant tissues in vivo VI. The role of hypotension in the action of components of podophyllin on transplanted sarcomas . J Natl Cancer Inst. 14:1954;879.
15. Stephens T.C., Peacock J.H. Cell yield and cell survival following chemotherapy of the B16 melanoma. Br J Cancer. 38:1978;591-598.
16. Baguley B.C., Holdaway K.M., Thomsen L.L., et al. Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine Evidence for a vascular mechanism . Eur J Cancer. 27:1991;482-487.
17. Hill S.A., Lonergan S.J., Denekamp J., et al. Vinca alkaloids Anti-vascular effects in a murine tumour . Eur J Cancer. 9:1993;1320-1324.
18. Hill S.A., Sampson L.E., Chaplin D.J. Anti-vascular approaches to solid tumour therapy Evaluation of vinblastine and flavone acetic acid . Int J Cancer. 63:1995;119-123.
19. Chaplin D.J., Pettit G.R., Parkins C.S., et al. Antivascular approaches to solid tumour therapy Evaluation of tubulin binding agents . Br J Cancer. 27:(Suppl.):1996;S86-S88.
20. Dark G.G., Hill S.A., Prise V.E., et al. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res. 57:1997;1829-1834.
21. Chaplin D.J., Pettit G.R., Hill S.A. Anti-vascular approaches to solid tumour therapy Evaluation of combretastatin A4 phosphate . Anticancer Res. 19:1999;189-195.
22. Tozer G.M., Prise V.E., Wilson J., et al. Combretastatin A-4 phosphate as a tumor vascular-targeting agent Early effects in tumors and normal tissues . Cancer Res. 59:1999;1626-1634.
23. Watts M.E., Woodcock M., Arnold S., et al. Effects of novel and conventional anti-cancer agents on human endothelial permeability Influence of tumour secreted factors . Anticancer Res. 17:1997;71-75.
24. Galbraith S.M., Chaplin D.J., Lee F., et al. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res. 21:2001;93-102.
25. Chaplin D.J., Dougherty G.J. Tumour vasculature as a target for cancer therapy. Br J Cancer. 80:(Suppl.):1999;57-64.
26. Tozer G.M., Kanthou C., Parkins C.S., et al. The biology of the combretastatins as vascular targeting agents. Int J Exp Pathol. 83:2002;21-38.
27. 2, microcirculatory function and radiosensitivity . Int J Radiat Oncol Biol Phys. 40:1998;943-951.
28. Smith K.A., Hill S.A., Begg A.C., Denekamp J. Validation of the fluorescent dye Hoechst 33342 as a vascular space marker in tumours. Br J Cancer. 57:1988;247-253.
29. Chalkley H.W. Method for the quantitative morphologic analysis of tissues. J Natl Cancer Inst. 4:1943;47-53.
30. Hamel E. Antimitotic natural products and their interaction with tubulin. Med Res Rev. 16:1996;207-231.
31. Chaplin D.J., Horsman M.R., Trotter M.J., et al. Therapeutic significance of microenvironmental factors. Molls M., Vaupel P. Medical radiology, diagnostic imaging and radiation oncology. Blood perfusion and microenvironment of human tumors. 1998;133-143 Springer-Verlag, Berlin, Heidelberg.
32. Li L., Rojiani A., Siemann D.W. Targeting the tumor vasculature with combretastatin A-4 disodium phosphate Effects on radiation therapy . Int J Radiat Oncol Biol Phys. 42:1998;899-903.
33. Grosios K., Loadman P.M., Swaine D.J., et al. Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma. Anticancer Res. 20:2000;229-233.
34. Murata R., Siemann D.W., Overgaard J., et al. Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors. Radiother Oncol. 60:2001;155-161.
35. Siemann D.W., Mercer E., Lepler S., et al. Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer. 99:2002;1-6.
36. Murata R., Overgaard J., Horsman M.R. Combretastatin A-4 disodium phosphate A vascular targeting agent that improves the anti-tumor effects of hyperthermia, radiation, and mild thermoradiotherapy . Int J Radiat Oncol Biol Phys. 51:2001;1018-1024.
37. Pedley R.B., Hill S.A., Boxer G.M., et al. Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin a-4 3-O-phosphate. Cancer Res. 61:2001;4716-4722.